Pharma Companies Stick To Their Roots In India As 40 Percent Yearly Growth Is In Sight
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Dusty roads, poor sanitation, rickety primary health centers, low income levels and sparse availability of qualified doctors - hardly a compelling environment for large pharmaceutical companies to grow their businesses but a few are bracing up to the challenges of the great Indian rural market
You may also be interested in...
Global Pharma Bidders May Queue Up For A Slice Of Mankind Pharma And Scorching 25 Percent Growth
MUMBAI - India's Mankind Pharma, which has seen exponential year-on-year growth of more than 25 percent, may be the latest attraction for large multinational pharma companies as speculation gathers steam that its deep roots in the largely untapped semi-urban and rural markets makes it an enviable takeover target
Global Pharma Bidders May Queue Up For A Slice Of Mankind Pharma And Scorching 25 Percent Growth
MUMBAI - India's Mankind Pharma, which has seen exponential year-on-year growth of more than 25 percent, may be the latest attraction for large multinational pharma companies as speculation gathers steam that its deep roots in the largely untapped semi-urban and rural markets makes it an enviable takeover target
Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
MUMBAI - Piramal Healthcare Chairman Ajay Piramal redefined the valuation processes for Indian life science companies last week, when he sold his domestic business of predominantly 350 branded generic products to Illinois-based Abbott for $3.72 billion - a jaw-dropping price that is nine times the level of annual sales and 31 times that of earnings